Parallax Volatility Advisers
LFCR icon

Parallax Volatility Advisers’s Lifecore Biomedical LFCR Stock Holding History

Parallax Volatility Advisers’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-37,600
Closed -$405K – 3485
2016
Q2 		$405K Buy
+37,600
New +$415K ﹤0.01% 1549

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Parallax Volatility Advisers's LFCR Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Lifecore Biomedical (LFCR) in Q1 2018, closing a stake of 4,158 shares — an estimated $52K sold.

Parallax Volatility Advisers first reported a position in LFCR in Q4 2014 and held it in 5 quarters. The position peaked at $274K in Q2 2016. 89 funds tracked by Wall St. Rank hold LFCR as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Lifecore Biomedical position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4,158 Lifecore Biomedical shares in Q1 2018, an estimated $52K.
  • Parallax Volatility Advisers first reported a position in Lifecore Biomedical in Q4 2014 and held it in 5 quarters.
  • Parallax Volatility Advisers's Lifecore Biomedical position peaked at $274K in Q2 2016.
  • 89 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.